BCRX · Biocryst Pharmaceuticals Inc
United States · RS rating 66 · As of 2026-11-03
| Price | 8.57 USD |
|---|---|
| 1-day change | +3.9% |
| RS rating (overall / 1M / 3M / 12M) | 66 / 73 / 55 / 66 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 44 / 39 / 58 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +1766.7% |
| Sales growth Q/Q | +155.1% |
| Distance from 52-week high | +22.9% |
| Market cap (USD) | $2.2B |